ICG and Sunitinib-loaded NH_(2)-MOFs for Folate-mediated Hepatocellular Carcinoma Dual-modal Therapy  

作　　者：ZHANG Zhoujing LIU Chuang Ozioma AKAKURU XU Wenjing WU Aiguo ZHANG Yewei 

机构地区：[1]School of Medicine,Southeast University,Nanjing,210009,P.R.China [2]Cixi Institute of BioMedical Engineering,CNITECH,Chinese Academy of Sciences,Ningbo,315201,P.R.China

出　　处：《Chemical Research in Chinese Universities》2021年第4期967-974,共8页高等学校化学研究（英文版）

基　　金：This work was supported by the Ningbo Natural Science Foundation,China(No.202003N4253);the Southeast University-China Pharmaceutical University Cooperative Research Project,China(No.2242019K3DZ06).

摘　　要：This research investigated a novel folic acid(FA)-modified zirconium core metal-organic framework(MOF)Uio-66 as a nanocarrier to deliver indocyanine green(ICG)and Sunitinib to cancer cells for combination therapy.Platinum-loaded Uio-66 nanoparticles(Pu)were synthesized via a one-pot method,followed by the modification with FA on their surfaces.This afforded FPu that enabled subsequent loading of ICG and Sunitinib to achieve dual-modal cancer therapy.Drug loading/release test and singlet oxygen detection were also conducted in vitro,and the nanoparticles showed considerable drug loading efficiency for both ICG and Sunitinib,coupled with a high singlet oxygen generation rate.Specifically,drug loading and encapsulation efficiency of Sunitinib were 2.30%and 72.67%,while those for ICG were 2.87%and 90.28%,respectively.Additionally,cytotoxicity test on HepG2 human hepatocellular carcinoma cancer cell line revealed that the fully functional nanoparticles possess excellent biocompatibility and as such could be further investigated as a potential drug delivery system for effectual carcinoma cancer treatment.

关 键 词：Metal organic framework Uio-66 Indocyanine green SUNITINIB Hepatocellular carcinoma 

分 类 号：R735.7[医药卫生—肿瘤]